Skye Bioscience (SKYE) Return on Capital Employed (2013 - 2026)
Skye Bioscience (SKYE) posted quarterly Return on Capital Employed of 438.91% for Q1 2026, down 38250.0% year-over-year from N/an in Q1 2025, and down 100.83% quarter-over-quarter from 218.55% in Q4 2025.
Skye Bioscience (SKYE) Return on Capital Employed (2013 - 2026) Analysis & Trends
Skye Bioscience (SKYE) has reported Return on Capital Employed for 14 consecutive years, with 438.91% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed fell 38250.0% year-over-year to 438.91%; the TTM figure through Mar 2026 stood at 438.91% (down 38250.0% YoY), while the FY2025 annual figure was 137.39%, down 5797.0% from the prior year.
- Return on Capital Employed slipped to 438.91% in Q1 2026 per SKYE's latest filing, from 218.55% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 27004.26% in Q4 2023 and bottomed at 1218.88% in Q2 2022.
- Historically, Return on Capital Employed has averaged 1592.38% across 5 years, with a median of 56.41% in 2025.
- Annual changes were most pronounced in 2023 — Return on Capital Employed jumped 2670550 bps — and 2024, when it tumbled 2704573 bps.
- Skye Bioscience's Return on Capital Employed stood at 298.76% in 2022, then surged by 8939 bps to 27004.26% in 2023, then plunged by 100 bps to 41.47% in 2024, then slumped by 427 bps to 218.55% in 2025, then tumbled by 101 bps to 438.91% in 2026.
- Business Quant data shows SKYE's Return on Capital Employed at 438.91% in Q1 2026, 218.55% in Q4 2025, and 140.55% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 26.09% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -50.93% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 7.88% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -6.85% |
| 10 | Skye Bioscience | 11.17 Mn | 11.17 Mn | - | -1,404.80% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -438.91% |
| Dec 31, 2025 | -218.55% |
| Sep 30, 2025 | -140.55% |
| Jun 30, 2025 | -90.98% |
| Mar 31, 2025 | -56.41% |
| Dec 31, 2024 | -41.47% |
| Sep 30, 2024 | -29.98% |
| Jun 30, 2024 | -56.50% |
| Mar 31, 2024 | -100.53% |
| Dec 31, 2023 | 27,004.26% |
| Sep 30, 2023 | 832.19% |
| Jun 30, 2023 | 283.34% |
| Mar 31, 2023 | 735.51% |
| Dec 31, 2022 | 298.76% |
| Sep 30, 2022 | 515.86% |
| Jun 30, 2022 | -1,218.88% |
| Mar 31, 2022 | -206.80% |
| Dec 31, 2021 | -114.42% |
| Sep 30, 2021 | -82.88% |
| Jun 30, 2021 | -164.92% |